Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Tarsons Products's Revenue for the
three
months ended in Jun. 2026 was ₹1,102 Mil. Tarsons Products's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹854 Mil.
Hence, Tarsons Products's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.29.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Tarsons Products Receivables Turnover Related Terms
Tarsons Products Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Tarsons Products's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543399 vs ISRG, BDX, RMD: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Tarsons Products's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsons Products Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tarsons Products's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Tarsons Products's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsons Products (BOM:543399) has a Receivables Turnover of 1.29 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tarsons Products and its competitors. According to the industry distribution chart, Tarsons Products ranks #408 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 50.2%.
Is Tarsons Products' Receivables Turnover too high?
Tarsons Products' current Receivables Turnover is 1.29. The Medical Devices & Instruments industry median Receivables Turnover is 5.58. Tarsons Products' value of 1.29 is 76.9% below this industry median. Based on the distribution chart, Tarsons Products ranks #408 out of 812 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Tarsons Products has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsons Products' Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tarsons Products ranks #408 out of 812 companies for Receivables Turnover. This places Tarsons Products in the lower half of its industry. The industry median Receivables Turnover is 5.58. Tarsons Products' value of 1.29 is 76.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.58, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tarsons Products's current Receivables Turnover of 1.29 is 76.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tarsons Products and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsons Products's current Receivables Turnover is 1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsons Products stock overvalued right now?
Based on GuruFocus' analysis, Tarsons Products (BOM:543399) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹468.88, compared to a current price of ₹331.05 — trading 29.4% below its estimated fair value. The current Receivables Turnover is 1.29 and 76.9% below the Medical Devices & Instruments industry median of 5.58. Tarsons Products' overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Tarsons Products (BOM:543399), the current Receivables Turnover is 1.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsons Products (BOM:543399) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsons Products stock appears to be undervalued.
The current stock price of ₹331.05 is trading 29.4% below its estimated GF Value™ of ₹468.88.
GuruFocus considers Tarsons Products to be Modestly Undervalued.
Key valuation signals for BOM:543399:
Receivables Turnover: 1.29
GF Value™: ₹468.88 vs. price of ₹331.05 (29.4% below fair value)
Industry Position: 76.9% below the Medical Devices & Instruments median (#408 of 812)
No single metric tells the full story. See the BOM:543399 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsons Products Ltd is an Indian labware Company engaged in designing, developing, manufacturing, and marketing consumables, reusables, and other including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, CROs, diagnostic companies, and hospitals. The Company is also engaged in the manufacturing of a wide range of quality labware products that help scientific discovery and improve healthcare. The company generates the majority of its revenue from the sale of manufactured plastic products. Geographically, the company generates the majority of its revenue from India.
84GF Score
Get the complete analysis for BOM:543399
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543399 has been successfully added to your 
